OraSure Technologies (NASDAQ:OSUR – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Thursday.
OraSure Technologies Price Performance
Shares of OraSure Technologies stock opened at $3.71 on Thursday. The stock’s 50 day simple moving average is $3.89 and its 200-day simple moving average is $4.12. The stock has a market cap of $276.74 million, a P/E ratio of 24.73 and a beta of 0.05. OraSure Technologies has a 1-year low of $3.52 and a 1-year high of $8.33.
OraSure Technologies (NASDAQ:OSUR – Get Free Report) last issued its earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. OraSure Technologies had a return on equity of 3.55% and a net margin of 5.07%. The business had revenue of $39.92 million during the quarter, compared to the consensus estimate of $38.97 million. During the same period last year, the company earned $0.27 EPS. The company’s revenue for the quarter was down 55.2% on a year-over-year basis. As a group, research analysts expect that OraSure Technologies will post -0.08 EPS for the current fiscal year.
Institutional Investors Weigh In On OraSure Technologies
OraSure Technologies Company Profile
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Featured Stories
- Five stocks we like better than OraSure Technologies
- 3 Stocks to Consider Buying in October
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Quiet Period Expirations Explained
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.